Advocate Lutheran General Hospital

Bone Metastases

Dr. John Han-Chih Chang
CRA Geralidine Asis
847.723.8239

Palliative
RTOG 0433 (4051):  A Phase III International Randomized Trial of Single versus Multiple Fractions for Re-Irradiation of Painful Bone Metastases

RTOG 0517 (4606):  Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breast, and Prostate Cancer, Cervical Carcinoma Limited to the Pelvis

HRPC
Algeta (pending):  Phase III Study of Alpharadin (Radium-223) in Patients with Symptomatic Hormone Refractory Prostate Cancer with Skeletal Metastases (ALSYMPCA)

Brain

Glioblastoma
RTOG 0825 (4812):  Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation And Adjuvant Temozolomide In Patients With Newly Diagnosed Glioblastoma
Dr. John Han-Chih Chang
CRA Geralidine Asis
847.723.8239

Breast

Diagnostic Testing
AHCIRB 4806:   A comparison of Short Acquisition Time Breast Tomosynthesis Mammography and Conventional Mammography in the Visualization and Characterization of Breast Calcifications
Dr. Sarah Maier Friedewald
CRA Maysoon Alrahi
847.723.8269 

Adjuvant Node Positive, High Risk Node Negative
NSABP B-46-I / USOR 07132 (4826):  Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Dr. Jacob Bitran
CRA Yelizaveta Yanovskaya
847.723.8927

DCIS
NSABP B-43:   A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Dr. Jacob Bitran
CRA Yelizaveta Yanovskaya
847.723.8927

Adjuvant Intermediate Risk
ECOG PACCT-1 (4188):  Program for the Assessment of Clinical Cancer Tests (PACCT-1)- Trial Assigning Individualized Options for Treatment.  The TAILORx Trial.
Dr. Sigrun Hallmeyer
CRA Geraldine Asis 
847.723.8239

In-House Study (3722):  A Phase I/II Trial Evaluating Accelerated Partial Breast Irradiation as Sole Treatment after Lumpectomy in Early Stage Breast Cancer Patients (Mammosite)
Dr. John Han-Chih Chang
CRA Geraldine Asis
847.723.8239

Adjuvant Intermediate Risk <50 years old
RTOG 0413/B-39 (3932):  Randomized Whole Breast Irradiation vs Partial Breast Irradiation for Women with Stage 0, I, or II Breast Cancer
Dr. John Han-Chih Chang
CRA Geraldine Asis
847.723.8239

Gynecologic

Dr. Timothy M. Lestingi / Dr. James R. Dolan
CRA Yelizaveta Yanovskaya
847.723.8927

Adjuvant High Risk Ovarian
GOG 0212 (4360):  Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103)(IND#70177) Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer who Achieve Complete Clinical Response to Primary Platinum/Taxane Chemotherapy

GOG 0252 (4792):  A Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy In Ovarian, Fallopian Tube, And Primary Peritoneal Carcinoma:  NCI-Supplied Agent:  Bevacizumab 

Stage IVB, Recurrent or Persistent Cervical
GOG 0240 (4884):  A Randomized Phase III Trial of Cisplatin Plus Paclitaxel with and without NIC-Supplied Bevacizumab (NSC#704865, IND #7921) Versus the Non-Platinum Doublet, Topotecan Plus Paclitaxel with and without   NCI-supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix

Adjuvant High Risk Endometrial
GOG 0249 (4845):  A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel / Carboplatin in Patients With High-Risk,Early Stage Endometrial Cancer

GOG 0258 (4846):  A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma 

Colorectal

NSABP - P-5: Statin Polyp Prevention Trial in Patients with Resected Colon Cancer
Dr. Jacob Bitran
CRA Maysoon Alrahi
847.723.8269 

Head & Neck

Esophageal
RTOG-0436 (4789):  A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer who are Treated without Surgery 
Dr. John Han-Chih Chang 
CRA Geralidine Asis
847.723.8239 

Hematologic

Dr. Jacob Bitran
CRN Mary Hurd            
847.723.8538

HSCT
AHCIRB# 3383:  Data Collection and reporting for Stem Cell Transplant Patients and Donors

AHCIRB# 2951:  Filgrastim-Mobilized Peripheral Blood Stem Cells for Primary Allogeneic Transplantation Unrelated Donors

Pelvic

AHCIRB 3660:  A Phase II Study of Amifostine to Reduce Acute and Long-Term Toxicity from Combined Chemotherapy and Pelvic Radiation
Dr. John Han-Chih Chang
CRA Geralidine Asis
847.723.8239 

Cancer Care & Hematology Specialists

Dr. Leonard Klein
CRA Pian Moy, RN
847.827.9060 

Bladder

USO 06040:  Phase ii Trial of Gemcitabine, Cisplatin, and Sunitinib in Patients with Advanced/Metastatic Urothelial Carcinoma Breast

Breast

ECOG 5103:  A Double Blind Phase iii Trial of Doxorubicin and Cyclophosamide, Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and  High Risk Lymph Node Negative Breast Cancer

ECOG N063D:  A Randomized Multi Centre Open Label Phase iii Study of Lapatinib Trastuzumab, Their Sequence and Their Combination in Patients with Her2/Erbb2 Positive Primary Breast Cancer.

adj/HER-2 +, node + or node -
USO 07119 BETH :  A Multicenter Phase ii Randomized Trial of Adjuvant Therapy for Patients with Her2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab

adj/HER2 +, pT1-3c
USO 08201:  A Randomized Double-Blind Placebo-Controlled Trial of Neratinib After Trastuzumab in Women with Early-Stage Her-2/Neu Overexpressed/Amplified Breast Cancer
 
metastatic, HER2 +
USO 09097:  A Randomized, Open-Label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued Her2 Suprression Therapy After Completion of First - or Second-Line Trastuzumab Plus Chemotherapy in Patients with Her2-Positive Metastatic Breast Cancer

metastatic, HER2 -
USO 08007:  Phase ii Trial of Ixabepilone Plus Carboplatin in Patients with Metastatic Breast Cancer

no met dis, <70 yrs
USO 07132:  A Phase iii Clinical Trial Comparing The Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, Her2-Negative Breast Cancer

Brain

ECOG E3F05:  A Phase iii Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade GliomasColorectal

Colorectal

CALGB 80405:  A Phase iii Trial of Irinotecan/5-Fu/Leucovorin or Oxaliplatin/5-Fu/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

ECOG 4203:  Phase ii Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Colorectal Ca

ECOG 5202:  A Randomized Phase iii Study Comparing 5 FU, Leucovorin, and Oxaliplatin Versus 5 FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage ii Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

ECOG 3205:  Phase ii Trial of Cetuximab Plus Cisplatin, 5 Fluorouracil and Radiation in Immunocompetent Patients with Anal Carcinoma

NSABP R-04:  A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma Of The Rectum

Endocrine

S0518:  A Phase iii Prospective Reandomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab in Advanced Poor Prognosis Carcinoid Patients

Gynecologic

Endometrial / Uterine
USO 09194:  An Open-Label, Single-Arm, Multicenter Phase 2 Study of E7080 in Subjects with Advanced Edometrial Cancer and Disease Progression Following First-Line Chemotherapy

Head & Neck

ECOG 1305:  A Phase iii Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer

Hematologic

CLL
USO 10034:  Connect - The Chronic Lymphocytic Leukemia Disease Registry

Leukemia
ECOG 1905:  A Randomized Phase ii Trial of Azacitidine with or without the Histone Deacetylast Inhibitor Ms 275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type) and Acute Myeloid Leukemia with Multilineage Dysplasia

Myeloma
USO 08209:  A Phase iii Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Mutliple Myeolma Patients Previously Treated with Bortezomib

MDS
ECOG 1905:  A Randomized PH ii Trial of Azacitidine with or without the Histone Deacetylast Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia (Dysplasia Type) and Acute Myeloid Leukemia with Multilineage Dysplasia

ECOG 2905:  Randomized Phase iii Trial Comparing the Frequency of Major Erythroid Response (Mer) to Treatment with Lealidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDs and Symptomatic Anmeia

Non Hodgkin
B cell
USO 09227:  An Open-Label Study To Evaluste The Efficacy And Safety Of Treatment With Bendamustine In Combination With Ofatumumab In Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma

Mantle cell
USO 08087:  An Open-Label, Single-Arm Phase ii Study of Rad001 in Patients with Refractory Mantle Cell Lymphoma Who Are Refractory or Intolerant of Velcade

Melanoma

ECOG 1697:  Randomized Study of Four Weeks High Dose
Ifn-Α2b In Stage T2b No, T3a-bNo, T4a-b No, and T1-4, N1a, 2a (microscopic) Melanoma

ECOG 2607:  A Phase ii Trial of Dasatinib in Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Solar Melanomas

Lung

NSCLC - RT not allowed
ECOG 1505:  A Phase iii Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> 4 CM) - IIIA Non-Small Cell Lung Cancer

IIIB/IV NSCLC
USO 07057:  Talactoferrin or Placebo + Best Supportive Care (BSC) 3rd/4th  Line NSCLC
  
IIIB/IV NSCLC
USO 08044: Randomized Open Label Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV NSCLC

NSCLC second line
USO 08094:  A Phase iii, Randomized, Double-Blind, Placebo-Controlled Mulit-Center Study of ASA404 in Combination with Docetaxel in Second-Line Treatement of Patients with Advanced or Metastatic (STAGE IIIB/IV) Non-Small Cell Lung Cancer

Prostate

ECOG 3805:  Chaarted: Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer

SWOG 0421:  Phase iii Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer
 
USO 09073:  A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone with or without Lenalidomide in Subjects with Castrate-Resistant Prostate Cancer

Renal

ECOG 2805: A Randomized Double Blind Phase iii Trial of Adjuvant Sunitnib VS Sorafenib VS Placebo in Patients with Resected Renal Cell Carcinoma

ECOG 2804:  The Best Trial: A Randomized Phase ii Study of Vegf RAF Kinase and M TOR Combination Targeted Therapy with Bevacizumab, Sorafenib & Temsirolimus in Advanced Renal Cell CA